Skip to content

Clinical Trials

Non-Small Cell Lung Cancer (NSCLC) Squamous

Learn More About Lung Cancer

For general information on lung cancer—including risk factors, symptoms, diagnosis, and treatment—visit the Cancer Council’s website:

Read More

General Enquiries

For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.

Enquiry Form
Protocol NumberCancer TypeStudy NameInterventionMechanism of ActionRecruitment StatusSponsorClinical.Trials.gov IDClick to Enquire
AWT020-001Non-Small Cell Lung Cancer (NSCLC) SquamousA Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients With Progressive Locally Advanced or Metastatic CancerImmunotherapyAnti-PD1 IL-2 BiTE.Open - RecruitingAnwita BiosciencesNCT06092580Enquire Now
PTT-4256-01Non-Small Cell Lung Cancer (NSCLC) SquamousA Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256.ImmunotherapyInhibitor of the pH-sensing G-protein-coupled receptor 65Open - RecruitingPathios Therapeutics Pty LtdNCT06634849Enquire Now
VRN110755Non-Small Cell Lung Cancer (NSCLC) SquamousA Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)TargetedSmall molecule EGFR inhibitor for EGFR-mutated NSCLCOpen - RecruitingVoronoi Therapeutics NCT07699328Enquire Now
SL-28-FIHNon-Small Cell Lung Cancer (NSCLC) SquamousA Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid TumoursImmunotherapyIV allogeneic, non-genetically modified cell-based therapyOpen - RecruitingSecond Life Therapeutics Pty Ltd.ACTRN12625001342404pEnquire Now